United Kingdom - English - myHealthbox

bristol-myers squibb pharma eeig - nivolumab - concentrate for solution for infusion - 10 mg/ml - antineoplastic agents, monoclonal antibodies - as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults

European Union - English - myHealthbox

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - film-coated tablet (tablet) - 30 mg - hepatitis c, chronic - direct-acting antiviral - indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults

European Union - English - myHealthbox

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - film-coated tablet (tablet) - 60 mg - hepatitis c, chronic - direct-acting antiviral - indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 200 mg/40 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - ipilimumab 5 mg/ml;   - concentrate for injection - 50 mg/10 ml - active: ipilimumab 5 mg/ml   excipient: hydrochloric acid mannitol nitrogen pentetic acid polysorbate 80 sodium chloride sodium hydroxide trometamol hydrochloride water for injection - yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma in adults, 18 years of age or older. yervoy, in combination with opdivo (ipilimumab), is indicated for the treatment of patients with unresectable or metastatic disease melanoma.

Israel - English - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - capsules - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

Israel - English - Ministry of Health

bristol - myers squibb, israel - entecavir; entecavir - film coated tablets - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease. baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - powder for concentrate for solution for infusion - abatacept 250 mg - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists. polyarticular juvenile idiopathic arthritis: orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).orencia is indicated for the prophylaxis of acute graft versus host disease (agvhd), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 6 years of age or older undergoing hematopoietic stem cell transplantation (hsct) from a matched or 1 allele-mismatched unrelated-donor.

Israel - English - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - solution for injection - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).

United Kingdom - English - myHealthbox

bristol myers squibb pharmaceuticals ltd. - pravastatin sodium - tablets - 20 mg - serum lipid reducing agents/cholesterol and triglyceride reducers/hmg-coa reductase inhibitors - treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate; reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet: reduction of cardiovascular mortality and morbidity in patients with a history of myocardial infarction (mi) or unstable angina pectoris and with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors; reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation